Overview

A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL

Status:
Recruiting
Trial end date:
2024-07-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the effectiveness and safety of polatuzumab vedotin in combination with R-miniCHP in patients 75 years and older with DLBCL.
Phase:
Phase 2
Details
Lead Sponsor:
University of Rochester
Collaborator:
Genentech, Inc.
Treatments:
Cyclophosphamide
Doxorubicin
Prednisone
Rituximab